ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,693.71
      1.41%
      US Tech 100
      19,230.00
      1.31%
      Dow Jones
      42,062.21
      1.16%
      Brent Oil
      70.65
      0.71%
      Bitcoin
      85,388.38
      3.23%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Anavex Life Sciences Corporation (AVXL) Quote

      Anavex Life Sciences Corporation

      Anavex Life Sciences Corporation (AVXL)

      NASDAQ
      9.80
      0.49
      ( 5.26% )
      Updated: 15:28:54
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      Key stats and details

      Current Price
      9.80
      Bid
      9.78
      Ask
      9.82
      Volume
      530,538
      9.2917 Day's Range 9.90
      3.25 52 Week Range 14.4405
      Market Cap
      833.629M
      Previous Close
      9.31
      Open
      9.31
      Last Trade
      9
      @
      9.8
      Last Trade Time
      15:28:54
      Financial Volume
      $ 5,091,865
      VWAP
      9.5975
      Average Volume (3m)
      1,487,569
      Shares Outstanding
      85,064,199
      Dividend Yield
      -
      PE Ratio
      -19.27
      Earnings Per Share (EPS)
      -0.51
      Revenue
      -
      Net Profit
      -43M

      About Anavex Life Sciences Corporation

      Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are u... Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2. Show more

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Biological Pds,ex Diagnstics
      Website
      www.anavex.com
      Headquarters
      Carson City, Nevada, USA
      Founded
      -
      Anavex Life Sciences Corporation is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker AVXL. The last closing price for Anavex Life Sciences was $9.31. Over the last year, Anavex Life Sciences shares have traded in a share price range of $ 3.25 to $ 14.4405.

      Anavex Life Sciences currently has 85,064,199 shares outstanding. The market capitalization of Anavex Life Sciences is $791.95 million. Anavex Life Sciences has a price to earnings ratio (PE ratio) of -19.27.

      Ask ADVFN Intelligence (AI)

      AVXL Latest News

      More News

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]
      Edgar (US Regulatory)
      February 12 2025
      AVXL (5.26%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      January 17 2025
      AVXL (5.26%)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10.657.103825136619.159.968.80018509379.17023142CS
      41.1212.90322580658.689.967.719671808.54560738CS
      12-1.042-9.6107729201310.84214.44057.71148756910.23766356CS
      264.1874.37722419935.6214.44055.0313769679.11112514CS
      524.95102.061855674.8514.44053.2512301297.17488682CS
      156-3.09-23.972071373212.8915.243.2511995118.33807568CS
      2607.49324.2424242422.3131.52.23134442610.74948097CS

      AVXL - Frequently Asked Questions (FAQ)

      What is the current Anavex Life Sciences share price?
      The current share price of Anavex Life Sciences is $ 9.80
      How many Anavex Life Sciences shares are in issue?
      Anavex Life Sciences has 85,064,199 shares in issue
      What is the market cap of Anavex Life Sciences?
      The market capitalisation of Anavex Life Sciences is USD 791.95M
      What is the 1 year trading range for Anavex Life Sciences share price?
      Anavex Life Sciences has traded in the range of $ 3.25 to $ 14.4405 during the past year
      What is the PE ratio of Anavex Life Sciences?
      The price to earnings ratio of Anavex Life Sciences is -19.27
      What is the reporting currency for Anavex Life Sciences?
      Anavex Life Sciences reports financial results in USD
      What is the latest annual profit for Anavex Life Sciences?
      The latest annual profit of Anavex Life Sciences is USD -43M
      What is the registered address of Anavex Life Sciences?
      The registered address for Anavex Life Sciences is 701 S CARSON ST, STE 200, CARSON CITY, NEVADA, 89701
      What is the Anavex Life Sciences website address?
      The website address for Anavex Life Sciences is www.anavex.com
      Which industry sector does Anavex Life Sciences operate in?
      Anavex Life Sciences operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      XHLDTEN Holdings Inc
      $ 1.305
      (123.00%)
      		179.53M
      LSELeishen Energy Holding Company Ltd
      $ 12.0705
      (55.35%)
      		14.63M
      BOWNUBowen Acquisition Corporation
      $ 7.40
      (52.58%)
      		34.94k
      BOWNBowen Acquisition Corporation
      $ 6.46
      (49.36%)
      		6.45M
      WHLRLWheeler Real Estate Investment Trust Inc
      $ 262.87
      (44.12%)
      		408
      WCTWellchange Holdings Company Limited
      $ 0.2343
      (-40.68%)
      		12.83M
      ONVOOrganovo Holdings Inc
      $ 0.2621
      (-35.11%)
      		3.25M
      KBSXFST Corporation
      $ 4.03
      (-26.59%)
      		4.2M
      JSPRWJasper Therapeutics Inc
      $ 0.1101
      (-23.49%)
      		1.28k
      BONBon Natural Life Ltd
      $ 0.3574
      (-23.35%)
      		27.58M
      NVDANVIDIA Corporation
      $ 119.0187
      (3.11%)
      		206.4M
      XHLDTEN Holdings Inc
      $ 1.305
      (123.00%)
      		179.53M
      TSLLDirexion Daily TSLA Bull 2X Trust ETF
      $ 8.275
      (10.78%)
      		132.86M
      SUNESUNation Energy Inc
      $ 0.458
      (17.14%)
      		119.64M
      LCIDLucid Group Inc
      $ 2.4574
      (4.57%)
      		112.62M

      AVXL Discussion

      View Posts
      ExtremelyBullishZig ExtremelyBullishZig 13 minutes ago
      Sounds painful. You might want to have that checked out...
      👎️ 1 👺 1
      Greenspam3 Greenspam3 18 minutes ago
      https://www.alzheimer-forschung.de/forschung/aktuell/blarcamesin/
      👍️ 2
      mike_dotcom mike_dotcom 28 minutes ago
      Don't jinx it George.
      👍️0
      Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 52 minutes ago
      C'mon, push that stock over $10 today

      So i can release the scalded cat!

      👍️ 1
      Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 56 minutes ago
      Dr. Maurice, Like Anavex Itself -- the Real Deal

      Great post. We are very well set up for Euro approval. Euro- led company, Euro advocates, Euro-based trials.
      👍️ 3 😃 2
      georgejjl georgejjl 59 minutes ago
      AVXL stock price is heading higher and higher. It appears that AVXL could and should close at the high of the day today!!!

      Good luck and GOD bless,
      👍️0
      falconer66a falconer66a 1 hour ago
      Dr. Maurice, Like Anavex Itself -- a Real Deal
      ...care to comment on Dr.Maurice's role re:Blarcamesine ???
      Well, Dr. Maurice is a member of the Anavex Scientific Advisory Board:
      Tangui Nicolas Maurice, PhD
      A member of the Scientific Advisory Board, Dr. Maurice has spent 15 years in the field of neurosciences, including behavioral and molecular neuropharmacology, sigma receptors, neuropeptides, neurosteroids, neurotrophic factors, normal/pathological aging models for Alzheimer’s and related disorders, and behavioral phenotyping of rodent models. Dr. Maurice is a researcher at the Institut national de la sante et de la recherche medicale (INSERM) U710 at Montpellier. He has also held research positions at the Centre National de la Recherche Scientifique (CNRS), INSERM U336, the department of neuropsychopharmacology and hospital pharmacy at Meijo University (Nagoya, Japan), and Jouveinal Research Institute (Fresnes, France).
      His name appears in many of the academic documents that tell of the development of Anavex's sigma-1 receptor agonists. Probably no other person better knows the chemistry and pharmacokinetics of Anavex's proprietary drug candidates. That he allows his professional membership on the Anavex board testifies to the validity and power of Anavex science. An expert such as this wouldn't align himself with a questionable biotech upstart that had no real future.

      Understand, Dr. Maurice is European, in France. For Anavex's application to get blarcamesine approved by the European Medicines Agency, for sale in Europe, surely Dr. Maurice's name has appeared in the application. The EMA will view him as a recognized, local expert.
      🎯 3 👍 2 👍️ 10 😃 1
      mauismart mauismart 1 hour ago
      Here comes a large buyer of avxl..now
      👍️ 4 🤓 2
      Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 1 hour ago
      No, that's wrong, very wrong.
      a lot of people stand to lose a lot of money if tiny Anavex succeeds in becoming the new SOC.
      There really isn't a standard of care, because nothing works. Aricept is off patent, Pfizer won't die on that hill. Being able to write off the MABs would be a blessing for their makers. They can quit wasting production on a product no one wants and blame it on 273.

      On the other side US health insurance cos will love 273. So will Medicare.

      Approval would be about as close a pure win as they come.

      👍️ 4 😃 2
      plexrec plexrec 2 hours ago
      "Dr. Tangui Maurice PhD is an inventor of Anavex 2-73"--thought so and agree !!!!
      🎯 1 👍️ 4 😃 1
      falconer66a falconer66a 2 hours ago
      Need a Contact Person
      A timely letter to RFK Jr. Introducing him to Anavex might be all that's needed to stop the big pharma manipulation.
      No, a mere letter to RFK Jr. won't do it. Will take more.

      A professionally written PDF that tells the Anavex story, that could be presented to RFK's office manager, could be very productive.

      I could construct such a document. Would take a day. Then a second re-edit day to make the final version. Lots of color graphics which concisely tell the validity of Anavex science, etc.

      If someone could post an appropriate contact person (with his or her email), I'll check it out and if he or she seems to be the appropriate contact I'll write the PDF and email it to the contact person.
      👍️ 6 💥 1 😃 1
      georgejjl georgejjl 2 hours ago
      Dr. Tangui Maurice PhD is an inventor of Anavex 2-73, blarcamesine

      https://ppubs.uspto.gov/dirsearch-public/print/downloadBasicPdf/9750746?requestToken=eyJzdWIiOiJhOThlZjI4YS00OTQ5LTRjODAtODM4MC1kZGNkZGNlMWM5YjciLCJ2ZXIiOiJkNjY3NzdjYS00MjMzLTQ0YmEtYWJiZC03NzM1MDIxN2RhYzciLCJleHAiOjB9

      Good luck and GOD bless,
      👍️ 2
      plexrec plexrec 2 hours ago
      " one of the KEY Opinion Leaders regarding"-----valuable person to have on our team !!!!!!!
      👍️ 3
      georgejjl georgejjl 2 hours ago
      Dr Tangui Maurice PhD is also an inventor of Anavex's blarcamesine.

      Good luck and GOD bless,
      👍️ 4
      subluxed subluxed 2 hours ago
      Dr Tangui Maurice is certainly one of the KEY Opinion Leaders regarding the Sigma Receptor.
      https://www.emedevents.com/speaker-profile/tangui-maurice
      https://www.mdpi.com/1422-0067/24/21/15868
      https://pubmed.ncbi.nlm.nih.gov/19619582/
      👍️ 3
      plexrec plexrec 2 hours ago
      falconer-----care to comment on Dr.Maurice's role re:Blarcamesine ???----https://en.wikipedia.org/wiki/Blarcamesine
      👍️0
      subluxed subluxed 2 hours ago
      The puzzle pieces are coming together.
      Dr Tangui Maurice
      Action Chair
      +33467143291
      tangui.maurice@umontpellier.fr

      https://www.cost.eu/actions/CA23156/#tabs+Name:Main%20Contacts%20and%20Leadership
      👍 3
      plexrec plexrec 2 hours ago
      subluxed--Not only is Dr Tangui Maurice---thought I read somewhere that Dr.Maurice was one of the inventors of "blarcamasine" ----anyone ??????
      👍️0
      subluxed subluxed 3 hours ago
      Not only is Dr Tangui Maurice the Action Chair of COST >>>>
      https://www.cost.eu/actions/CA23156/#tabs+Name:Management%20Committee
      he is also a scientific advisor for Anavex.
      The sigma-1 receptor (S1R) is a ligand-regulated endoplasmic reticulum chaperone protein and a target for innovative compounds for the treatment of neurodegenerative and inflammatory diseases, cancers and pain diseases. The SIGMA-1 EUROPE network will bring together disciplines and expertises across Europe to advance the exploration and identification of the role of S1R in physiology and pathologies, to design innovative S1R ligands for cellular biology and medicine, and ultimately to train Young Reserachers and Innovators to revise current views of the diseases, to think out-of-the-box and explore novel and innovative S1R-based therapeutic opportunities.

      Sigma -1 receptor is getting a lot more attention and Blarcasamine will be the breakthrough drug that will prove it.
      🎯 3 👍️ 12
      falconer66a falconer66a 3 hours ago
      Alzheimer's Association Blarcamesine Silence --- For Now
      Why is it that Anavex is never mentioned by the Alzheimer’s Association and other groups that are still pushing the BP’s mabs?
      Why would the Alzheimer's Association be telling how blarcamesine is going to revolutionize Alzheimer's treatment?

      First, their Alzheimer's experts are as good as those that post on this investor message board, naysaying anything and everything "Anavex." Don't ya know? True experts tell about and endorse ONLY drugs that have already been approved by the FDA and can be prescribed by "real doctors." Right now, blarcamesine fits neither of those criteria.

      And, I suppose (well, you suppose) that Alzheimer's patients and their caregivers always check with the Alzheimer's Association whenever a doctor prescribes something.

      "Dear Alzheimer's Association, My wife with Alzheimer's just got a prescription for the new drug 'blarcamesine.' Should she take it?"

      After the FDA or European Medicines Agency approve blarcamesine in their jurisdictions, will this be the Alzheimer's Association statement to blarcamesine inquires?"

      "Yes, blarcamesine has now been approved by the FDA or EMA. But we can't endorse its use. Too inexpensive to be a real Alzheimer's treatment. Far less than $3000,000 a year. Stay with the monoclonal antibody drugs that have earned billions of dollars for the drug companies that developed them. A ten dollar a day drug can't fix Alzheimer's."
      🏆️ 1 👍 4 🧠 1
      k9uwa k9uwa 3 hours ago
      "A timely letter " One day after 2-73 is accepted by EMA Every one of us from I-Hub and ask all from ST's all write a letter and send it to FDA RFK
      That will get their attention.
      John k9uwa
      🎯 4 👍️ 5 👎️ 1 👺 1
      123tom 123tom 3 hours ago
      A timely letter to RFK Jr. Introducing him to Anavex might be all that's needed to stop the big pharma manipulation. The corruption of the rockafella medical system is being dismantled.
      👍️ 4 👎️ 1 👺 1 😸 1 🤣 1
      RedShoulder RedShoulder 3 hours ago
      European Network for Sigma-1 Receptor as a Therapeutic Opportunity (SIGMA-1EUROPE)

      The sigma-1 receptor (S1R) is a ligand-regulated endoplasmic reticulum chaperone protein and a target for innovative compounds for the treatment of neurodegenerative and inflammatory diseases, cancers and pain diseases. The SIGMA-1 EUROPE network will bring together disciplines and expertises across Europe to advance the exploration and identification of the role of S1R in physiology and pathologies, to design innovative S1R ligands for cellular biology and medicine, and ultimately to train Young Reserachers and Innovators to revise current views of the diseases, to think out-of-the-box and explore novel and innovative S1R-based therapeutic opportunities.

      https://www.cost.eu/actions/CA23156/#tabs+Name:Description

      Thanks to Topgum on ST for the find.
      👍️ 8 😃 2
      rx7171 rx7171 3 hours ago
      There always seems some ways to tweak patent extensions but I doubt if brand loyalty will mean much unless the Anavex price approaches that of the generics.
      Still lots of runway ahead.
      👍️ 3
      Lacey1 Lacey1 3 hours ago
      Word of mouth will take care if that. It will spread quickly because you sleep better right off the bat.
      👍️ 4
      hnbadger1 hnbadger1 3 hours ago
      You don’t think that the big advocacy groups are in the back pocket of the large BPs?
      Why is it that Anavex is never mentioned by the Alzheimer’s Association and other groups that are still pushing the BP’s mabs?
      Why is it that after a very positive OLE trial and successful peer review along with an EMA filing, Anavex is very much unheard of.
      Because a lot of people stand to lose a lot of money if tiny Anavex succeeds in becoming the new SOC.
      👍️ 11 🔥 2 🔦 1
      Investor2014 Investor2014 3 hours ago
      Yes and that is one of the requirements for MAA approval.
      👍️ 2
      falconer66a falconer66a 4 hours ago
      Big Pharma "Bushback?" Sure.
      Having Merck or Roche’s name attached to it would give a lot more credibility to this disruptive new approach to treating AD.
      "More credibility..." ...than to have hundreds of Alzheimer's patients, caregivers, and medical personnel report on how patients on blarcamesine are now sleeping well, have reduced or absent angriness, and are just simply feeling better?

      Blarcamesine becoming the new SOC will surely have a lot of pushback from many different parties that stand to lose billions from this new, cheaper, effective treatment.
      Ok, then tell us what this massive "pushback" is going to push back on. Who gets shoved?

      "Hey, we are a big drug company that is suffering. Our $300,000 per year monoclonal antibody Alzheimer's drug isn't being bought or used anymore. This new 'blarcamesine' stuff has to be made illegal."

      Health insurance companies are really gonna push back on blarcamesine, aren't they? They have so much to gain from the MABS, don't they?

      And after blarcamesine is on the market, Trump's FDA and CDC are gonna be really receptive for the pushback.
      👍️ 3
      frrol frrol 4 hours ago
      You have a poor understanding of biotech M&A. You can relax.
      👎️ 3 👺 1
      found_it2 found_it2 4 hours ago
      And up today on very low volume....
      👍️ 2
      hnbadger1 hnbadger1 4 hours ago
      Anavex can probably handle the EU market without a partner with their socialized medicine system. The EU governments would support their cheaper, easier and more effective alternative.
      The US market will be a different ball game. Not an easy task for a tiny, unknown biotech to overtake the huge AD market.
      👍️ 3
      dia76ca dia76ca 4 hours ago
      But they could tinker with the drug. And Brand Loyalty would occur!
      👍️ 3
      tschussmann1 tschussmann1 4 hours ago
      Not sure there are as many vested interests in Europe against Anavex as there would be in the US. Also, a BP partner is going to have their name associated with the drug, Anavex will not get much publicity. Dr Missling said they were exploring innovative paths to commercialization...I hope a standard low royalty partnership is not included.
      👍 6 😃 1
      dia76ca dia76ca 4 hours ago
      Cats!
      👍️ 1 😸 1
      rx7171 rx7171 4 hours ago
      We would eventually bump up against the time limits of our patents.
      So at least 10-15 years of exclusivity.
      👍️ 3 😃 1
      Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 4 hours ago
      PETA? Better hide

      👍️ 1 😆 2
      dia76ca dia76ca 4 hours ago
      Scientists such as Dr. Gambelle believe that the Mode of Action of Blarcamesine and A2-371 could be effective against virtually every CNS disease. This means that these drugs could become part of the Standard of Care for all CNS diseases around the world! But the largest single use of these drugs could be as a prevention of brain shrinkage beginning in a person's forties. As many people will live healthfully into their 90's with the assistance of these drugs the 40-50 year income flow to Anavex will be enormous! I don't know of any better biotech investment!
      👍️ 6 😀 2 😃 1
      Steady_T Steady_T 4 hours ago
      I'm not informed enough to have an opinion of how much push back there might be.
      My thought is that the single payer systems will be looking at the cost VS not using 2-73 and creating a push to use 2-73.
      I live in the US so the internal working of the single payer systems is not something I have much knowledge of.

      We shall see.

      I trust Missling to make a good deal for Anavex when the time is right.
      👍️ 11
      hnbadger1 hnbadger1 4 hours ago
      As much as I would like see Anavex market Blarcamesine alone and keep all the profits, I believe we would do better with a strong BP partner, at least to get the ball rolling with AD.
      Having Merck or Roche’s name attached to it would give a lot more credibility to this disruptive new approach to treating AD.
      Blarcamesine becoming the new SOC will surely have a lot of pushback from many different parties that stand to lose billions from this new, cheaper, effective treatment.
      A deep pocketed BP will give the muscle and credibility to help Anavex succeed in its first and massive entrance into the pharmaceutical space.
      Once a solid foundation is set with AD, A371 and the smaller indications can be handled by Anavex alone.
      👍️ 6 💯 3
      Steady_T Steady_T 4 hours ago
      I'm reporting you to PETA.

      If you are going to scald a cat, at least get the SP to $40. 😇
      👍️ 2 🤣 4
      Citrati Citrati 4 hours ago
      Price setting higher highs and higher lows. Today price has tested upper line of trend channel and the 50 period. Ideal would be closing above the top horizontal blue line and the 50period and continue building strong support structure for sustaining higher prices as strong news is reported.

      Patiently waiting on consistent 2million+ green volume days and some monster days 5million+.

      https://investorshub.advfn.com/uimage/uploads/2025/3/19/dkugvScreen_Shot_2025-03-19_at_9.08.06_AM.png
      👍️ 5 😃 1
      k9uwa k9uwa 4 hours ago
      "quantity manufactured" From memory TGD said over a year ago they had TWO companies making the drug. One in Ireland and another in some EU country.
      John k9uwa
      👍️ 3
      IhidfromtheX IhidfromtheX 5 hours ago
      Buy another million and maybe it will! It's more like we'll go up a penny a day or week until $20...Mike will be happy!
      👍️ 2
      Steady_T Steady_T 5 hours ago
      One can make the case that AD has such a large unmet need that the AD advocacy groups and the media will create a lot of public and Dr. awareness for Blarcamesine when it is approved.

      Another factor in Anavex's favor is that there really isn't any good treatment for AD, so 2-73 is not competing in the marketplace with other drugs.
      If there were other reasonable treatments available that 2-73 had to compete with, then marketing and a marketing organization would be a requirement.

      Partnering with a BP that has marketing and distribution would be a great approach IF the partnership deal is a good one for Anavex.
      If such a deal is not forthcoming it apprears to me that Anavex is preparing to go it alone initially.

      We shall see how things turn out. Got to get approved first.
      👍️ 8 😀 2 😃 1
      Steady_T Steady_T 5 hours ago
      My point was that Anavex has already had quantity manufactured according to Missling.
      👍️ 3 😃 1
      Guzzi62 Guzzi62 5 hours ago
      No, I have to agree.

      In the days when SAVA was a cult stock, one sentence from the CEO (the cheating one) and the SP rocketed.

      It seems some people are suspicious after that stunt, but I don't see why people are comparing us with them?

      This ex-con is still short here, I believe, and he has some followers, see some of them post on Stocktwist now and again.

      I think they will be talking about the OLE extension trial next month, let's hope that will get us going.

      Oh, and March 20th, transitioning from phase IIB/III success to commercial activities by Daniel Klamer VP- business development?
      👍 4 😃 1
      LakeshoreLeo1953 LakeshoreLeo1953 5 hours ago
      While the Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon

      Who pray tell is "our" in your advertisement?
      👍️0
      LakeshoreLeo1953 LakeshoreLeo1953 5 hours ago
      Had dinner with the wife last night locally.
      Next table, the former trainer for Washington Capitols '94-'15.
      His would have been the blocking and tackling assignment.
      He would argue that Ovechkin (talent) is important.

      Hopefully for Anavex Blarcamesine is the the Ovechkin analogy.
      👍️ 2 😃 1
      rx7171 rx7171 5 hours ago
      Yes us retail shareholders take all the risk to support small biotechs knowing there is historically a high probability the investment will not ultimately succeed.

      BP waits until the few successful ones rise to the top, buy them out for a fraction of their real potential worth and cash in on the risk taken by the little guys like us.

      Anavex is in a uniquely strong position with no debt and cash in hand with a drug to become SOC in probably the most profitable indication in the world.

      I trust Missling’s business experience to not partner or sell cheap.
      I hope the BOD lets him do it his way.
      🎯 7 🏆️ 1 👍️ 20 😀 2 😃 1
      found_it2 found_it2 5 hours ago
      "Zacks Recommendation Upgrades Mueller Water and Anavex Life Sciences"

      Shares of Mueller Water Products, Inc. MWA and Anavex Life Sciences Corp. AVXL have advanced 15.6% (versus the S&P 500’s 7.2% fall) and 2.4% (versus the S&P 500’s 5.8% fall) since their Zacks Recommendation was upgraded to Outperform on January 23 and January 20, respectively.

      While the Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon, the Zacks Recommendation aims to predict performance over the next 6 to 12 months. However, just like the Zacks Rank, the foundation for the Zacks Recommendation is trends in earnings estimate revisions.

      The Zacks Recommendation classifies stocks into three groups — Outperform, Neutral and Underperform. While these recommendations are determined quantitatively, our analysts have the flexibility to override them for the 1100+ stocks they closely follow based on their better judgment of factors such as valuation, industry conditions and management effectiveness than the quantitative model.
      👍️ 3 😃 1

      Your Recent History

      NASDAQ
      AVXL
      Anavex Life Sciences
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads